Human evidence record · Glutathione
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
No statistically significant difference in UPDRS change versus placebo.
Quick read
Human evidence record
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Who was studied?
People with Parkinson's disease whose motor symptoms were not adequately controlled
How many?
n=21
What happened?
No statistically significant difference in UPDRS change versus placebo.
What stops us overclaiming?
Very small disease-specific pilot; does not support general wellness or skin-lightening IV use.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
No statistically significant difference in UPDRS change versus placebo.
Study details
Study designRandomized, double-blind, placebo-controlled pilot trial
PopulationPeople with Parkinson's disease whose motor symptoms were not adequately controlled
Sample size21
RouteIntravenous
Regimen / exposure1,400 mg three times weekly
Duration4 weeks + 8-week observation
ComparatorPlacebo
Primary endpoint / questionSafety/tolerability and preliminary UPDRS efficacy
Safety resultIV glutathione was reported as generally well tolerated in this small trial.
Key limitationsVery small disease-specific pilot; does not support general wellness or skin-lightening IV use.
Registry / identifierPMID 19230029